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Concerns regarding a drought in psychopharmacology have risen from many quarters.
From one perspective, the wellspring of bedrock medications for anxiety disorders,
depression, and schizophrenia was serendipitously discovered over 30 year ago, the
swell of pharmaceutical investment in drug discovery has receded, and the pipeline’s
flow of medications with unique mechanisms of action (i.e., glutamatergic agents, CRF
antagonists) has slowed to a trickle. Might oxytocin (OT)-based therapeutics be an oasis?
Though a large basic science literature and a slowly increasing number of studies in human
diseases support this hope, the bulk of extant OT studies in humans are single-dose
studies on normals, and do not directly relate to improvements in human brain-based
diseases. Instead, these studies have left us with a field pregnant with therapeutic
possibilities, but barren of definitive treatments. In this clinically oriented review, we
discuss the extant OT literature with an eye toward helping OT deliver on its promise
as a therapeutic agent. To this end, we identify 10 key questions that we believe future
OT research should address. From this overview, several conclusions are clear: (1) the
OT system represents an extremely promising target for novel CNS drug development;
(2) there is a pressing need for rigorous, randomized controlled clinical trials targeting
actual patients; and (3) in order to inform the design and execution of these vital trials,
we need further translational studies addressing the questions posed in this review.
Looking forward, we extend a cautious hope that the next decade of OT research
will birth OT-targeted treatments that can truly deliver on this system’s therapeutic
potential.
Keywords: oxytocin, pharmacology, humans, intranasal administration, psychiatry, drug development
OXYTOCIN: TOOL OR TREATMENT?
Over the last several decades, the nonapeptide oxytocin (OT) has
been cast in two roles on the stage of human neuroscience. First
and most dramatic has been its remarkable and ever-expanding
role as a powerful mediator of myriad aspects of our uniquely
social brains (MacDonald and MacDonald, 2010). Beginning
with its evolutionary origin 10,000 years ago—when the progen-
itor nonapeptide vasotocin was orchestrating decision-making in
marine animals (Grimmelikhuijzen and Hauser, 2012)—a series
of vital advances have ratcheted forward our understanding of
this vital central system. These include its initial discovery as a
uterotonic component of pituitary extract over a century ago
(Dale, 1906); the concept (novel at the time) of neurosecretion,
the “glandular activity” of hormone-secreting neurons (Scharrer
and Scharrer, 1945); the vital technique of immunoflourescent
visualization of OT-producing neurons (Swaab et al., 1975)
which allowed the subsequent histological characterization of the
human central OT system (Loup et al., 1991); the more recent
sequencing and synthesis of the peptide (Du Vigneaud, 1956),
and the gene for the receptor (Kimura et al., 1992); and finally,
increasingly sophisticated translational research using techniques
like gene knockout and optogenetic manipulation of specific cen-
tral circuits (Stoop, 2012). Each of these progressive steps has
allowed us to ask and answer increasingly specific questions about
the nature of the central OT system and its contribution to
the bonded, social nature we share with fellow mammals. The
culmination of several decades of sophisticated translational neu-
roscience research has been a decade-long groundswell of human
studies which have ensconced OT and its sister nanopeptide vaso-
pressin with testosterone, estrogen, and cortisol in the pantheon
of centrally active hormones critical to understanding human
behavior.
OT has also been cast for a second, as-yet unfulfilled role as
a therapeutic tool to ameliorate suffering from brain-based dis-
ease. Promise notwithstanding, its performance here has been a
bit more pedestrian. Although it has been safely used for decades
in obstetrics to induce and augment labor, the suggestion that
OT may have therapeutic value in the treatment of a host of
brain-based conditions (addiction, anxiety, autism, mood disor-
ders, and schizophrenia) has not for the most part been bolstered
by clinical investigations with meaningful therapeutic endpoints.
More precisely, despite an enormous amount of anticipation that
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OT’s effects in preclinical studies can be translated into OT-based
treatments for psychiatric disorders, few studies have actually
delivered OT as a bona-fide therapeutic agent, using chronic daily
dosing, targeting core symptoms of specific disease states, and
assessing safety, tolerability, and clinical outcomes. From a clin-
ical perspective, the current portfolio of OT research is flush with
more therapeutic hints than help, and exogenous OT has—thus
far—acted more decisively in its role as a pharmacological probe
than a therapeutic palliative.
These contrasting roles come into apposition at a time in
the history of psychiatric therapeutics which some have called
a “crisis” (Fibiger, 2012). To whit, despite significant advances
in our understanding of the brain bases of human psychiatric
disease, our abilities to reduce suffering and restore function in
psychiatric disease remains woefully inadequate (Holma et al.,
2008; Lieberman and Stroup, 2011; Volkow and Skolnick, 2012).
Many or most of the foundational therapeutic medications in our
psychiatric armamentarium (i.e., antidepressants, antipsychotics)
were discovered serendipitously decades ago. Several promising
new therapeutic classes of drugs for CNS conditions have failed
to pass late-stage drug development. Stymied by these repeated,
costly product failures, many pharmaceutical companies have
abjured investing in this therapeutic arena. These pharmaceuti-
cal realities stand in stark contrast to the significant prevalence
and toll of brain-based diseases. Though these setbacks pose
a challenge to drug development, we maintain optimism that
OT-based therapeutics may provide relief, though as discussed
below, development of OT-targeted therapeutics has its own
challenges.
In this review, we approach OT from the perspective of
researcher-clinicians interested in the development of OT-
targeted pharmaceuticals for the abridgement of human psy-
chiatric disease. Given intense interest in this molecule and the
ever-mushrooming literature, this review has a necessarily limited
scope. Herein, we constrain our discussion to arenas of signifi-
cant, direct relevance to the development of OT-based therapeu-
tics, and direct interested readers to several recent, well-referenced
reviews on other vital aspects of OT including details of its neu-
rophysiology and interaction with arginine vasopressin (AVP)
(Stoop, 2012), implications of genetic variations in the OT recep-
tor (OTR; Ebstein et al., 2012; Kumsta and Heinrichs, 2013), and
OT’s role in human development (Gordon et al., 2011; Feldman,
2012).
BRAIN DISORDERS FORWHICH OXYTOCIN MAY HAVE
THERAPEUTIC EFFICACY
As mentioned above, as the result of its revealed effects on behav-
ior and brain processes observed in both animal studies and trans-
lational studies in humans, OT has been proposed as a potential
treatment for a wide range of brain disorders: addiction, anxiety
disorders, autism-spectrum and other developmental disorders,
borderline personality disorder, mood disorders, and schizophre-
nia. For a more complete background on OT’s preclinical profile
and the justification for these therapeutic speculations see the fol-
lowing recent, extensive reviews (Slattery and Neumann, 2010;
MacDonald and Feifel, 2012a; McGregor and Bowen, 2012; Modi
and Young, 2012; Neumann and Landgraf, 2012). As of November
2012, we note ongoing treatment trials of intranasal (IN) OT in
autism, schizophrenia and schizoaffective disorder, frontotempo-
ral dementia, major depressive disorder and treatment resistant
depression, post-traumatic stress disorder, borderline person-
ality disorder, and drug dependence (i.e., alcohol, marijuana)
(www.clinicaltrials.gov). Therewith, we anticipate that the next
several years will show a corresponding increase in actual clin-
ical data. To date, however, there have been a relatively limited
number of patient-targeted clinical OT trials, with the majority
being single-dose (Table 1). Given the limited number of studies
that have been conducted evaluating OT’s potential as a bona-fide
treatment for clinical brain disorders, one could conclude that
almost all of the much-anticipated therapeutic potential of this
neuropeptide remains to be proven.
IMPORTANT QUESTIONS FOR DEVELOPING
OXYTOCIN-TARGETED THERAPEUTICS
Most preclinical and translational studies conducted to date—as
well as single-dose studies in normals—attempt to answer the
question: “what does OT do?” A pragmatic, treatment-oriented
clinician may wish to restate the question, asking: “what does
OT do when used as drug?” More specifically, “what effects does
OT have when given chronically to patients with psychiatric ill-
ness?” Sadly, in spite of a decade of high-profile studies, we
would be hard-pressed to answer this question for the majority
of putative indications. Delving deeper, three-linked facts make
this clinically oriented query even more incisive: (1) as men-
tioned, the vast majority of published OT studies are single-dose
studies in normals; (2) in normals, the single-dose effects of
lifesaving psychiatric medications [i.e., antipsychotics, serotonin
reuptake inhibitors (SSRIs)] are often either negligible (Harmer
et al., 2003; Murphy et al., 2009) or aversive (Belmaker and
Wald, 1977; Harmer et al., 2008); (3) in psychiatric patients, the
short-term effects of some medications are the opposite of their
effect when given chronically [i.e., short-term anxiogenesis with
SSRIs (Kent et al., 1998)]. As such, though in some cases single-
dose effects in normals can be linked to longer-term benefits in
patient populations [i.e., enhancement of emotional processing
as a biomarker for antidepressant activity (Harmer et al., 2009a;
Tranter et al., 2009)], we should be circumspect when extrapolat-
ing too directly from these studies to the effects of chronic dosing
in psychiatrically ill samples. For all these reasons, multi-week,
daily dose, randomized placebo-controlled trials—the mainstay
for evaluating the therapeutic efficacy and safety of investigational
psychotropic drugs—are needed to advance the field from the
stage of optimistic speculation into the realm where definitive
verdicts can be obtained. Only then will we be able to deci-
sively answer the vital question asked by our treatment-seeking
clinician.
Beyond these sorely needed proof-of-concept clinical trials, the
development of OT-targeted therapeutics for CNS disease faces a
significant number of challenges. In the sections below—in the
form of 10 questions—we attempt to identify and describe them
(Table 2). En toto, these questions span a wide spectrum of issues
that need to be addressed in order to complete the bench-to-
bedside arc with OT. Of note, the question of the role of several
important individual factors (variations in the OT and CD38
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Table 2 | Ten questions for the development of oxytocin-targeted
therapeutics for brain disorders.
1. How do acute and chronic oxytocin administration differ?
2. How do oxytocin’s therapeutic-like effects in healthy subjects
translate to patient with brain disorders?
3. How do oxytocin’s therapeutically relevant effects differ in men and
women?
4. What is the optimal therapeutic dose range for oxytocin?
5. What is oxytocin’s optimal therapeutic dosing schedule?
6. Can native oxytocin be improved upon?
7. Is intranasal delivery of oxytocin the optimal route?
8. What is the role of vasopressin receptors in oxytocin’s effects?
9. Monotherapy vs. augmentation: can oxytocin treat on its own or is it
better suited to augment other established treatments?
10. Are there identifiable biomarkers for oxytocin’s therapeutic effects?
receptor, sex, and early experience) in clinical response to OT is
covered in an accompanying mini-review (MacDonald, 2012) in
this special section.
HOW DOES ACUTE AND CHRONIC OXYTOCIN ADMINISTRATION
DIFFER?
The vast majority of published studies of IN OT—even those
done in patient samples (Table 1)—have used only a single-
application dosing paradigm. In stark contrast, almost all treat-
ments for the most debilitating brain disorders are delivered
chronically, with most achieving their maximal clinical effects
after weeks of daily administration. Furthermore, as intimated
above, the acute and chronic effects of medications are often dia-
metrically opposite, as seen in the case of SSRIs, which are a
first-line chronic treatment for anxiety disorders, yet can cause
anxiety after a single-dose (Spigset, 1999; Birkett et al., 2011).
One process that contributes to the difference between acute
and chronic drug administration is “tachyphylaxis” or “toler-
ance” in which the acute effects of a drug dissipate with repeated
administration. At a cellular level, persistently stimulated recep-
tors like the OTR may become desensitized or may be expressed
in smaller numbers on cell surfaces, via several processes, includ-
ing one called internalization. Notably, internalization has been
demonstrated to occur with the OTR (Gimpl and Fahrenholz,
2001).
Specifically in the case of OT, basic science research supports
the fact that that there are often significant differences between
the effects of acute and chronic administration of OT (Kramer
et al., 2003; Bowen et al., 2011; Keebaugh and Young, 2011; Bales
and Perkeybile, 2012). Furthermore, though the neurobiological
mechanism of certain of OT’s effects (i.e., acute anxiolysis) have
been carefully dissected in animal models (Viviani and Stoop,
2008; Yoshida et al., 2009; Viviani et al., 2011; Knobloch et al.,
2012; Stoop, 2012, for review), the mechanism of action of ther-
apeutic later-onset effects of chronic OT treatment—the mode
of treatment most salient to human brain disorders—remains
unknown.
On this latter point, the small body of research in which
chronic IN OT has been given to psychiatrically ill patients indi-
cates that like currently used medications from other classes,
IN OTs antipsychotic (Feifel et al., 2010, 2012a; Pedersen et al.,
2011; Modabbernia et al., 2013) and anxiolytic (Feifel et al.,
2011) effects may take weeks to emerge to a clinically meaningful
degree. Unfortunately for the development of OT-targeted ther-
apeutics, then, the large number of extant IN OT studies may
not speak directly to key issues relevant to the effects of chronic
OT administration. As discussed below in section “What is the
Role of Vasopressin Receptors in Oxytocin’s Effects?” however, the
discovery and development of biomarkers which track with clin-
ical outcomes and syndromes would significantly improves the
clinical gain from single-dose trials (de Oliveira et al., 2012a).
Examples relevant to OT include the abovementioned single-dose
antidepressant effects on emotional processing (Harmer, 2008)
and the attenuation of the anxiogenic effects of CO2 inhala-
tion (Bailey et al., 2007). We anticipate that future biomarker
and pharmacokinetic studies in humans treated with acute and
chronic OT will build on the few single-dose, functional-imaging
trials in humans with psychiatric illness (Labuschagne et al., 2010,
2011; Pincus et al., 2010) to illuminate these important clinical
questions.
HOW DO OXYTOCIN’S THERAPEUTIC-LIKE EFFECTS IN HEALTHY
SUBJECTS TRANSLATE TO PATIENT WITH BRAIN DISORDERS?
A second pharmacodynamic issue that requires more study con-
cerns the difference between OT’s effects in normal vs. psychiatri-
cally ill samples. Just as a host of individual differences signifi-
cantly influence response to OT in normal samples (MacDonald,
2012), so it is likely that OT’s effects will differ between healthy
and clinical populations. For example, in a functional imaging
study of the effects of OT on brain activity during the read-
ing the mind in the eyes test (RMET), OT-mediated alteration
in brain activity differed significantly between untreated patients
with depression and normal subjects (Pincus et al., 2010). A
second, unpublished set of data from our group found that
patients with depression had an anxiogenic response to single-
dose IN OT given in a psychotherapy context, in contrast to
acute anxiolytic effects reported in normals (Heinrichs et al.,
2003; de Oliveira et al., 2012a,b). Additionally, Bartz et al. has
demonstrated that many patients with borderline personality
disorder have divergent responses to OT that those seen in nor-
mals, with OT-decreasing trust and cooperation (Bartz et al.,
2011a). On the other hand, some acute neural responses (atten-
uation of amygdala activity) are seen in both patient groups
(Labuschagne et al., 2010) and normals (Zink and Meyer-
Lindenberg, 2012) (Figure 1). Notwithstanding these similarities,
the findings from several single-dose studies indicating that the
effects of OT may differ between patients with psychiatric disease
and those without calls for caution when extrapolating clini-
cal effects of OT in patients from the study of its effects in
normals.
There may be, moreover, significant associations between the
OT system and certain psychiatric disease states or endophe-
notypes. One component of this distinction is covered in an
accompanying mini-review (MacDonald, 2012), which discusses
the clinical import of research on variations in the OTR and the
CD38 ectoenzyme. Though many of the studies in this growing
literature are in normals, certain genetic variations in aspects of
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FIGURE 1 | Intranasal oxytocin: potential therapeutic regulation of brain
function in psychiatric illness. Several important aspects of intranasally
delivered OT (IN OT) treatment of brain-based illness are represented. One
potential way that IN OT may cross the blood-brain barrier and cause
central effects is represented: directly via extraneuronal/perineuronal routes
along trigeminal or olfactory nerve pathways (Thorne and Frey, 2001; Ross
et al., 2004; Dhuria et al., 2010; Renner et al., 2012a,b). Other mechanisms
of entry (bulk flow, lymphatic channels, intraneuronal transport, active or
passive transport from vasculature) are discussed in references and the
text. IN OT may cause some of its central effects by stimulating the
endogenous OT system, which secretes OT into the peripheral circulation
(right pullout), and has both direct, “wired” and diffusion-mediated central
effects (Landgraf and Neumann, 2004; Stoop, 2012). Through these
mechanisms, IN OT impacts the function of amygdala-anchored
connectivity networks in normals (Kirsch et al., 2005; Sripada et al., 2013),
as well as important brain regions (amygdala, insula, anterior cingulate,
medial prefrontal cortex) in patients with psychiatric illness (Labuschagne
et al., 2010, 2011; Pincus et al., 2010). For simplicity, not all brain areas
impacted by OT are shown; see Bethlehem et al. (2012); Zink and
Meyer-Lindenberg (2012) for recent, detailed reviews.
the OT system have been associated with disease states (Kumsta
and Heinrichs, 2013). In addition to these known variations
in the OT system, one could assume that certain individuals
(and perhaps certain diagnostic groups) have an as-yet undoc-
umented state of more significant functional OT deficiency akin
to that found in central diabetes insipidus (DI). Specifically, in
the genetic form of central DI called familial neurohypophyseal
diabetes insipidus (FNDI), variations in the AVP prohormone
gene (AVP-neurophysin II) on chromosome 20 result in inade-
quate protein folding and dimerization. These changes cause the
aberrant protein to be retained in the neuron, ultimately lead-
ing to cell death of hypothalamic magnocellular neurons in the
supraoptic nucleus and paraventricular nucleus (Bergeron et al.,
1991; Ito and Jameson, 1997). Given endogenous AVPs role in
natriuresis, these patients present clinically with symptoms of
progressive functional AVP deficiency, including polyuria, and
polydipsia (Robertson, 1995). Currently, more than 60 clinically
relevant genetic variants of the AVP prohormone have been iden-
tified (Christensen et al., 2013). Returning to OT, then, variants of
“OT deficient” animals have been created via genetic alterations of
the OT gene or its receptor (Young et al., 1996; Bernatova et al.,
2004; Lee et al., 2008; Nishimori et al., 2008): these animals dis-
play a range of behavioral abnormalities. As such, although no
OT-related genetic syndrome akin to FNDI has yet been charac-
terized in humans, the abovementioned findings raise the inter-
esting question of the possibility of an “OT-deficiency syndrome”
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which manifests with deficits in the production and/or function
of either the hormone, the receptor, or other components of the
system (i.e., the ectoenzyme CD38).
HOW DO OXYTOCIN’S THERAPEUTICALLY RELEVANT EFFECTS DIFFER
IN MEN ANDWOMEN?
Given OT’s intimate evolutionary involvement with reproductive
function, it should not be surprising to find that is has distinct
effects on the brains of males and females. Indeed, the histological
structure for OT neurons is sexually dimorphic (de Vries, 2008)
and sex biases in behavioral responses to OT have been frequently
found in animal studies (Williams et al., 1994; Cho et al., 1999;
Bales and Carter, 2003; Bales et al., 2007a). Estrogen increases OT
and OTR production (Patisaul et al., 2003; Windle et al., 2006;
Choleris et al., 2008), whereas testosterone promotes hypothala-
mic OTR-binding (Johnson et al., 1991) as well as production of
AVP (Delville et al., 1996), which has many opponent actions to
OT (Neumann and Landgraf, 2012).
Though the question of the meaning and measurement of
OT levels is still subject to active study (see section “What is
Oxytocin’s Optimal Therapeutic Dosing Schedule?” below), men
and women show differences in plasma OT levels (Ozsoy et al.,
2009; Gordon et al., 2010; Holt-Lunstad et al., 2011; Weisman
et al., 2012c), as well as sex-specific behavioral correlations
with OT (Gordon et al., 2010; Zhong et al., 2012). In addi-
tion, amygdala-prefrontal cortical connectivity—which can be
impacted by OT in normal subjects (Sripada et al., 2013) and
anxiety patients (Labuschagne et al., 2011)—may be related in a
gender-specific way to the development of anxiety and depressive
disorders (Burghy et al., 2012). Furthermore, numerous stud-
ies in the growing OTR literature note sex-specific associations
between genetic variants in the OTR gene and personality charac-
teristics (Stankova et al., 2012), neural responses to emotionally
salient cues (Tost et al., 2010), pair-bonding (Walum et al., 2012),
hypothalamic gray matter volume (Tost et al., 2010), and empa-
thy (Wu et al., 2012). On the other hand, several studies in
this area have failed to find a sex bias (Rodrigues et al., 2009;
Saphire-Bernstein et al., 2011; Feldman, 2012).
With regards to clinical studies of the effects of IN OT, a sex
difference in its effects has been demonstrated in some single-
dose studies (Hurlemann et al., 2010), including studies of OT’s
effects on the amygdala (Domes et al., 2010; Rupp et al., 2012),
and interpersonal behavior (Liu et al., 2012). Again, these effects
are variable: many other studies in this area have not found an
effect of sex [see Bartz et al. (2011b), for review].
Focusing on the few multi-week clinical trials of OT in psychi-
atric populations, the three published clinical trials in schizophre-
nia included a disproportionate number of males (62 males
treated vs. 13 females), consistent with most clinical trials of
this disorder (Feifel et al., 2010, 2012a; Pedersen et al., 2011;
Modabbernia et al., 2013). The number of women included in
each trial was not sufficient to analyze for a sex-by-drug effect.
Though schizophrenia is the clinical disorder with the largest
number of separate randomized trials using IN OT, the first study
to intimate a sex moderation effect of OT was a randomized,
double-blind, within-subjects crossover study of OT (40 IU BID
for 3 weeks) in patients with generalized anxiety disorder (GAD)
(Feifel et al., 2011). This trial demonstrated a trend-level dose-by-
gender effect such that males treated with OT showed a significant
clinical improvement in HAM-A scores with OT, whereas females
did not. En toto, the abovementioned sex differences indicate that
delineation of the role of sex and sex hormones in the response to
chronic OT treatment will be critical.
WHAT IS THE OPTIMAL THERAPEUTIC DOSE RANGE FOR OXYTOCIN?
Despite the groundswell of IN OT research, we know very little
about either the optimal dose or dosing parameters of IN OT for
any CNS indication, and single-dose studies, though informative,
speak somewhat peripherally to this important issue. Noteworthy
is that animal research indicates a discrepancy between the effects
of both dose (Windle et al., 1997; Kramer et al., 2003; Bales
et al., 2007b) and single vs. chronic dosing of OT (Bales and
Perkeybile, 2012). Aside from optimizing therapeutic effect, dos-
ing issues are also important in terms of side effects, given that
OT has some cross-affinity with AVP receptors which mediate its
potential diuretic and natriuretic effects (Gimpl and Fahrenholz,
2001), and have been noted in a single case report of high-
dose IN OT (Ansseau et al., 1987). An illuminating primate
study in this regard indicated that perhaps due to cross-reactivity
with AVP, [which potentiates stress responses (Legros, 2001)],
chronic higher-dose IN OT (200 IU) did not attenuate cortisol
(ACTH) responses, whereas a lower-dose (50 IU) did (Parker
et al., 2005).
Largely due to prior precedent (vs. pharmacological rationale),
the majority of published human studies have tested OT in single
doses in the 20–40 IU range (MacDonald et al., 2011a), though
doses as low at 10 IU (Goldman et al., 2011) and as high as 160
IU daily (Epperson et al., 1996a,b) have been reported. The few
chronic-dosing studies cited herein have used a dose range of
24–40 IU BID (Feifel et al., 2010, 2012a; Pedersen et al., 2011;
Modabbernia et al., 2013). Importantly, very few studies have
directly compared the effects of two or more doses, a standard
strategy in dose-finding clinical trials.
In one the first clinical study to examine effects of multi-
ple doses of OT in the same clinical subject, Goldman et al.
demonstrated that in patients with schizophrenia, 10 IU caused
a decrement in ability to identify facial emotions (due to
increased false-response rate), whereas 20 IU improved emo-
tion recognition in polydipsic relative to non-polydipsic patients
(Goldman et al., 2011). This dose-related finding is interesting
given that more placebo-controlled IN OT trials have been done
in schizophrenia than any other indication. In a study of men
with fragile X syndrome, 24 IU but not 48 IU IN OT improved
eye gaze frequency, whereas 48 IU but not 24 IU decreased social-
stress induced salivary cortisol levels (Hall et al., 2012). A study
in normals on the effect of OT on exercise-induced increased in
salivary cortisol levels demonstrated that 24 IU but not 48 IU
attenuated this effect (Cardoso et al., 2012). Another related study
in normal men found that IV OT (titrated to a level 10 times
higher than physiologically normal baseline levels) demonstrated
a linear, dose-response OT effect on ACTH and cortisol (Legros
et al., 1984). Finally, a recent study documented that salivary OT
levels in normal subjects remained similarly elevated for up to
7 h, regardless of which of 2 doses of IN OT patients received
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(16 or 24 IU) (van Ijzendoorn et al., 2012). In light of these find-
ings suggesting that OT’s effects may be dose-dependent, more
studies are needed in which more than 1 dose—preferably a range
of doses—are directly compared. Clearly, we need to understand
whether a dose-response relationship exists regarding the effects
of OT on core disease symptoms, andwhether such dose-response
relationships are disease specific.
WHAT IS OXYTOCIN’S OPTIMAL THERAPEUTIC DOSING SCHEDULE?
In addition to an inadequate understanding regarding the dose-
response curve for most therapeutically relevant effects of OT,
there is very little known regarding its optimal therapeutic-
dosing frequency (e.g., once daily, twice daily, etc.). In addition
to knowing the optimal dose range, dose frequency data is criti-
cal for successful design of future proof-of-concept clinical trials.
Typically, dosing schedule is based upon the plasma half-life of
the drug in question. However, this heuristic is likely not applica-
ble to the CNS effects of OT, particularly OT delivered IN, given
its putative direct access to the brain via this route of admin-
istration (Born et al., 2002). Specifically, whereas the plasma
half-life of IV OT is less than 10min (Mens et al., 1983), it
lasts much longer in the CSF, and studies measuring plasma OT
have found elevated levels of the peptide lasting more than 1 h
after a single IN administration (Burri et al., 2008; Gossen et al.,
2012).
Relevant here are single-dose studies measuring both salivary
(Huffmeijer et al., 2012; Weisman et al., 2012a) and plasma OT
levels (Burri et al., 2008; Andari et al., 2010; Domes et al., 2010;
Gossen et al., 2012), which indicate that IN OT quickly ele-
vates peripheral OT levels, and that, these levels remain above
baseline for some time. In terms of mechanism, in addition to
direct absorption via the nasal vasculature, it is thought that IN
OT may also elevate peripheral OT levels by entering the brain
and stimulating OT neurons to secrete endogenous OT from
central stores into the peripheral circulation (Neumann et al.,
1996) (Figure 1). This suggestion is supported by the fact that
OT neurons operate in a feed-forward “bursting” mechanism,
such that exogenous or endogenous OT stimulates further pul-
satile OT release (Renaud et al., 1984; Rossoni et al., 2008), part
of a locally regulated positive-feedback mechanism (Neumann
et al., 1996). This ongoing release from endogenous OT stores,
mediated partially through glutamatergic mechanisms (Jourdain
et al., 1998; Israel et al., 2003), could certainly contribute to the
sustained peripheral blood levels seen in IN OT studies. After
IN delivery, peripheral OT levels are elevated starting between
10 (Andari et al., 2010) and 30 (Gossen et al., 2012) min and
stay elevated for between 150min (Gossen et al., 2012) to sev-
eral hours (Burri et al., 2008; van Ijzendoorn et al., 2012), in
spite of OTs short plasma half-life (Mens et al., 1983). Vitally,
it is currently impossible to distinguish between transnasally
absorbed exogenous OT and endogenously secreted OT, so the
relative contribution of these two sources to subsequently mea-
sured OT levels is unknown. Moreover, though animal studies
have demonstrated some concordance between intraneuronal lev-
els of OT and peripheral OT levels (Wotjak et al., 1998; Cushing
and Carter, 2000; Wigger and Neumann, 2002), and though sev-
eral human studies show concordance between peripheral OT
levels and naturalistic, centrally mediated behaviors (i.e., parent-
ing, breastfeeding) (Feldman, 2012; Weisman et al., 2012b; for
review), the concordance between OTmeasured in different body
spaces (saliva, plasma, CSF) and central effects is still a matter of
active debate (Carter et al., 2007; Neumann, 2007).
A variety of important controversies and questions surround
the measurement of OT levels. Though space does not permit a
full elaboration on the topic, its relevance to many of the ques-
tions in this review warrants a discussion. First, we note that
there have been controversies regarding the validity and reliabil-
ity of measurement of OT levels in urine (Anderson, 2006; Young
and Anderson, 2010), saliva (Horvat-Gordon et al., 2005), and
plasma (Szeto et al., 2011) [and see references in Carter et al.
(2007); Szeto et al. (2011); Weisman et al. (2012c); Zhong et al.
(2012)]. One aspect of this controversy regards the measurement
of OT via immunoassay: the most cost-effective measurement
technique for large samples. Notably, a recent report questioned
both (1) the accuracy of both radioimmunoassays (RIA) and
enzyme immunoassays (EIAs) and (2) the necessity of the techni-
cal step of sample extraction which can changes by up to 100-fold
the measured levels of the peptide (Szeto et al., 2011). Most
recent studies that measure either plasma or saliva OT levels use
a commercial OT-Elisa kit (Assay-Design, MI, USA), which has
been validated for linearity, cross reactivity, matrix effects, accu-
racy, precision, and recovery (Carter et al., 2007) though the
use of extraction techniques in different studies is variable. In
support of the validity of this assay, across a broad range of dif-
ferent studies—including several very large samples (Weisman
et al., 2012c; Zhong et al., 2012)—these techniques have pro-
duced congruent results, with most of them finding reasonable
correlations between saliva and plasma OT levels (Grewen et al.,
2010; Feldman et al., 2011; Hoffman et al., 2012), and between
OT levels and a wide range of OT-dependent biological pro-
cesses (White-Traut et al., 2009; Grewen et al., 2010; Feldman,
2012).
A second, related issue surrounding the measurement and
meaning of peripheral OT levels is that of endogenous fluctua-
tions in OT levels. Though OT has a diurnal rhythm of daytime
rise and night-time decline in mice (Zhang and Cai, 2011) and
primates (Amico et al., 1990), the bulk of data does not sup-
port significant diurnal variations in plasma OT in humans
(Amico et al., 1983; Kuwabara et al., 1987; Challinor et al.,
1994; Kostoglou-Athanassiou et al., 1998; Turner et al., 2002;
Graugaard-Jensen et al., 2008), [but see Forsling et al. (1998),
Landgraf et al. (1982) for evidence of a nocturnal nadir]. CSF lev-
els may differ, as there is some evidence for a diurnal variation
in this body space (Amico et al., 1983; Kuboyama et al., 1988).
These data on circadian fluctuations stand apart from studies
of dynamic fluctuations in OT levels in states like pregnancy
(Kuwabara et al., 1987; Fuchs et al., 1992; Lindow et al., 1996),
breastfeeding (Jonas et al., 2009; Grewen et al., 2010), orgasm
(Carmichael et al., 1987), parenting (Feldman, 2012), and certain
stressors (Nussey et al., 1988; Sanders et al., 1990). Also related are
documented increases in peripheral OT levels due to both natural
variations in estrogen levels (Mitchell et al., 1981; Shukovski et al.,
1989) and the ingestion of exogenous estrogen which is known
to increase the magnocellular release of OT (Wang et al., 1995)
www.frontiersin.org March 2013 | Volume 7 | Article 35 | 9
MacDonald and Feifel Oxytocin-based therapeutics for brain disorders
and plasma OT levels (Amico et al., 1981; Silber et al., 1987;
Uvnas-Moberg et al., 1989; Michopoulos et al., 2011). Adding
complexity is that data on fluctuations in plasma OT levels across
the menstrual cycle are mixed, with studies in different healthy
and clinical populations showing both variation (Shukovski et al.,
1989; Salonia et al., 2005; Liedman et al., 2008) and lack of varia-
tion (Stock et al., 1991; Kostoglou-Athanassiou et al., 1998; Light
et al., 2005) in normally cycling women, with both estrogen and
progesterone levels playing a role.
A third, yoked pair of topics related to OT levels are (1) the cor-
relations between peripheral and central OT levels (see discussion
above) and (2) the correlation of OT levels and different disease
states. Regarding the latter, investigators have studied OT levels
and their relationship to aspects of autism (Modahl et al., 1998;
Al-Ayadhi, 2005), eating disorders (Hoffman et al., 2012; Lawson
et al., 2012), post-traumatic stress disorder (Seng et al., 2013),
schizophrenia (Goldman et al., 2008; Keri et al., 2009; Rubin
et al., 2011), social anxiety disorder (Hoge et al., 2008, 2012) and
depression (Scantamburlo et al., 2007; Parker et al., 2010). An
important but uninvestigated clinical question is whether a tran-
sient or chronic increase of peripheral OT levels via treatment
with IN OT (Andari et al., 2010; Gossen et al., 2012) corre-
lates with OT-responsive clinical symptoms or treatment-related
symptomatic improvement (e.g., whether OT levels may function
as a biomarker).
Returning, then, to the clinical issue of OT dose and frequency:
though the abovementioned studies of OT levels,—including
post-dose OT levels—are somewhat informative regarding the
task of determining an optimal OT dose and frequency, to date,
there have been no published studies examining the time course
of the brain-mediated effects of IN OT, nor of their correlation
with peripheral OT levels. Such studies would greatly enhance
our ability to optimize OT dose frequency for therapeutic ends.
In fact, most studies of IN OT in humans examine its effects
at a single time point, typically 30–60min after administration.
For these reasons, in addition to studies examining a range of
doses of IN OT, studies examining OT’s brain effects over a
range of time points are needed to inform optimal OT treatment
design.
CAN NATIVE OXYTOCIN BE IMPROVED UPON?
Though the native nonapeptide OT has significant advantages in
terms of therapeutic modulation of the central OT system, there
are problems with peptides. Specifically, neuropeptides like OT
lack many “drug-like” properties, especially as regards CNS indi-
cations. Though they have certain advantages over other chemical
medicinal classes (i.e., evolved specificity for unique functions
and receptors, limited drug–drug interactions, little accumulation
in tissues, few side-effects), neuropeptides also carry unique lia-
bilities as medications related to their molecular nature (Manning
et al., 2012;McGonigle, 2012). These shortcomings include a brief
plasma half-life and poor oral bioavailability due to their degrada-
tion by plasma and gastric proteases, as well as limited penetrance
of the blood-brain barrier due to their large size and hydrophilic
nature (McGonigle, 2012).
Technological advances in medicinal chemistry, however,
are providing specific solutions to these challenges. In a few
cases, medicinal chemists have managed to design small non-
peptidergic molecules that bind a specific peptide receptor and
are either inactive at that receptor (antagonist) or mimic the
actions of the endogenous peptide (agonist). In general this strat-
egy has been much more successful in producing antagonists
than agonists (Manning et al., 2012). However, the corpus of
preclinical and translation research with OT suggests that it is
OT agonists, not antagonists, that have promise as treatments
for several psychiatric disorders. With regards to OT, several
low-molecular weight non-peptidergic OT agonists have been
developed that penetrate the brain after peripheral administra-
tion (Pitt et al., 2004; Ring et al., 2010). The only non-peptide
OT agonist with experimental evidence for an OT-like behavioral
profile is WAY-277464, which had 87% of the binding affin-
ity of OT and significant greater selectivity for the OTR (Ring
et al., 2010). Though it exhibited an OT-like anxiolytic behavioral
and physiological profile in several animal tests (four-plate test,
elevated zero maze, stress-induced hyperthermia), and also an
OT-like preclinical antipsychotic profile [reversing amphetamine-
and MK-801-induced disruption of prepulse inhibition (PPI)],
it did not have an OT-like antidepressant profile [no reduced
immobility in the tail suspension test (TST)] (Ring et al., 2010).
An interesting corollary finding in this study—one that speaks
to the mechanism of action of OT’s antidepressant-like effects
in the TST—was that a selective OTR antagonist failed to block
these antidepressant effects, indicating WAY-27744’s effect may
be mediated through a different receptor system (i.e., AVPR: also
infra vida section “Is Intranasal Delivery of Oxytocin the Optimal
Route?”) (Ring et al., 2010) and raising similar questions for OT.
In any case, as a result of both pharmacological and market fac-
tors, development of WAY-277464 was not pursued by Wyeth
(Manning et al., 2012).
Because of the difficulty of developing a non-peptide OT ago-
nist, medicinal chemists have utilized another approach to the
problem of stimulating the OT system: chemical modification
of the native peptide or an active fragment to increase its resis-
tance to enzymatic degradation and increase metabolic stability.
This process has produced carbetocin: an uterotonic OT analog
with a peripheral half-life of 85–100min, significantly longer than
OT’s (Hunter et al., 1992). Carbetocin—produced by Ferring
Pharmaceuticals—is approved in 23 countries outside the United
States for post-partum hemorrhage, but there are no published
studies investigating its CNS effects in humans. Though a potent
uterotonic agent, carbetocin has about 10-fold lower affinity for
the OTR than OT (Engstrom et al., 1998; Gimpl et al., 2005), and
has been shown to lack anxiolytic efficacy (elevated plus maze)
when delivered peripherally, vs. OT, which has anxiolytic effi-
cacy when delivered peripherally (McCarthy et al., 1996; Ring
et al., 2006). In another experiment, peripheral carbetocin failed
to produce antipsychotic-like effects on PPI (Feifel et al., 2012b).
Interestingly, carbetocin did demonstrate an antidepressant-like
profile in the forced swim test when administered peripherally
and centrally (Chaviaras et al., 2010), and does have short-term
anxiolytic effects when delivered centrally (Mak et al., 2012). It
would be very instructive to determine carbetocin’s effects on
centrally mediated processes, especially on clinical symptoms of
pyschiatric disorders in humans.
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Besides biochemical modifications of the molecules them-
selves, alternative drug delivery systems (i.e., patches, micro-
spheres, liposomes) can also improve the pharmacokinetic profile
of peptides and represent another approach to addressing the
challenges of therapeutic modulation of endogenous peptide sys-
tems (Patil and Sawant, 2008; Manning et al., 2012; McGonigle,
2012). As an example, a mucoadhesive buccal OT patch has been
tested in animals and was able to deliver OT continuously over 3 h
(Li et al., 1997). Notably, the efficacy of this or other alternative
OT delivery systems on centrally mediated processes has not yet
been tested in human or animal studies.
Aside from the delivery of OT or non-peptide OT analogs
to the CNS, there are several other ways to impact the central
OT system [reviewed in Modi and Young (2012)]. These include
inhibition of the non-specific enzyme that degrades OT in the
CSF [aminopeptidase placental-leucineaminopeptidase (P-LAP)
(Chai et al., 2008; Albiston et al., 2011)] and the use of drugs
that may stimulate OT release from endogenous stores via the
serotonergic (Jorgensen et al., 2003a) and melanocortin receptors
(Sabatier, 2006) found on OT neurons. Drugs like the sero-
tonin 1a agonist buspirone (Bagdy andKalogeras, 1993; Jorgensen
et al., 2003b), 3,4 methlyenedioxymethamphetamine (MDMA)
or ecstasy (Thompson et al., 2007; Dumont et al., 2009; Broadbear
et al., 2011), and the uniquely effective antipsychotic clozaril
(MacDonald and Feifel, 2012a), have been proposed to exert some
of their pharmacological activity via stimulation of the central OT
system.
IS INTRANASAL DELIVERY OF OXYTOCIN THE OPTIMAL ROUTE?
As mentioned above, a prominent pharmacokinetic issue with
synthetic OT involves getting this relatively large, hydrophilic
molecule into the brain, given its poor penetration of the blood-
brain barrier (McEwen, 2004). IN application of peptidergic
drugs to the CNS has been proven since 1989 (Frey, 1991), and
is a delivery system increasingly utilized for a variety of drugs
for a range of putative central indications, including memory
(Benedict et al., 2007) and multiple sclerosis (Ross et al., 2004).
Delivering a peptide IN capitalizes first on the heavily vascularized
nasal mucosa, which drains through both fenestrated epithelium
and via several facial veins (facial and sphenopalatine), into the
peripheral circulation, circumventing first pass metabolism (Zhu
et al., 2012). In this way, IN delivery simulates IV delivery: drugs
delivered IN may reach the brain via active transport or diffusion
from the blood compartment across the blood-CSF or blood-
brain barrier (Thorne and Frey, 2001; Morimoto et al., 2009).
Beyond this, a direct-to-the-brain path of entry after IN delivery
of peptides and other drugs has been proposed via two possible
mechanisms (Figure 1): (1) intraneuronal active uptake along the
olfactory or trigeminal nerve into the brain; and (2) extraneu-
ronal passive diffusion into the CSF through perineural clefts in
the nasal epithelium which provide a gap in BBB (Illum, 2004;
Thorne et al., 2004; Renner et al., 2012a,b) and (Dhuria et al.,
2010; Chapman et al., 2012; Zhu et al., 2012 for references and
details).
In point of fact, direct-to-the-brain delivery of IN OT was
extrapolated from studies with OT’s sister nanopeptide vaso-
pressin, which differs from OT by the substitution of two amino
acids (Riekkinen et al., 1987; Born et al., 2002). These studies
found that IN delivery increased both CSF levels and plasma lev-
els of AVP (Riekkinen et al., 1987; Born et al., 2002). Indirect
support for this hypothesis comes from findings that both vaso-
pressin and OT administered IN have central effects [Fehm et al.
(2000) and references therein]. Though contemporary critiques
have raised important questions about the details of whether nasal
OT gets directly into the brain, and if so, how (Churchland and
Winkielman, 2012), support for the direct-to-brain notion comes
from recent studies in primates that found that IN OT doubles
CSF OT levels within 35min (Chang et al., 2012), strong evi-
dence of central penetration, given that extant evidence supports
that endogenous OT in the CSF derives from central not periph-
eral sources (McEwen, 2004). Further support comes from recent,
unpublished rodent data indicating that IN OT elevates OT lev-
els in the extracellular fluid in the hippocampus and amygdala
(Rainer Landgraf, pers. communication). Studies with other IN-
delivered peptides showing perineuronal transport are also of
interest in this regard (Chen et al., 1998; Renner et al., 2012b;
Zhu et al., 2012). On the other hand, increased central levels
of OT after IN administration can occur indirectly via elevated
levels of OT in the peripheral circulation, thus the evidence
described above does not represent definitive evidence of a direct
nose-to-brain mechanism, nor whether IN-administered OT has
advantages over peripheral or even orally administered OT in
terms of brain penetration or reduced peripheral side effects.
Indeed, at least one study examining this issue concluded that
Devunetide (an 8-amino acid peptide) administered IN to rats
entered the brain via the peripheral blood system (Morimoto
et al., 2009). As such, given potential disadvantages of IN delivery
(i.e., reliance on patients for consistent dose delivery), the issue of
whether the IN route or another route is optimal for OT-targeted
therapeutics is still an open question.
WHAT IS THE ROLE OF VASOPRESSIN RECEPTORS IN OXYTOCIN’S
EFFECTS?
Due to their close evolutionary relationship, the pharmaco-
logical story of the OT system is interleaved with that of its
“sister” hormone AVP. Pivotally, though they have evolved to
serve very different functions, these two neuropeptides differ by
only 2 amino acids (Gimpl and Fahrenholz, 2001). In terms
of receptors, 4 G-protein-coupled receptors have been iden-
tified that bind these peptides in both humans and rodents:
AVPR1a, AVPR1b, AVPR2, and OTR (Gimpl and Fahrenholz,
2001; Grimmelikhuijzen and Hauser, 2012). Of these receptors,
AVPR1a is the most abundantly expressed in the brain, whereas
AVPR1b has more limited brain expression and AVPR2 exists
almost exclusively in the periphery (Stoop, 2012). Pertaining
to OT-directed therapeutics, it is important to note that OT
is relatively selective, binding to AVP receptors with ∼1% the
affinity it binds to OTRs, whereas AVP is non-selective, bind-
ing with similar affinity to both OTR and AVPRs (Lowbridge
et al., 1977; Mouillac et al., 1995; Manning et al., 2012). Also
important is that population-level genetic studies of OT and
AVPR1a receptors in humans indicate that both systems appear
to be responsible for important behavioral phenotypes in humans
(Prichard et al., 2007; Walum et al., 2008, 2012; Levin et al., 2009;
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Meyer-Lindenberg et al., 2009; Kumsta and Heinrichs, 2013). In
terms of conceptualizing their role in mammalian behavior, it
appears that differences in receptor co-expression and region-
specific density—parameters which vary meaningfully in rodents
(see Veinante and Freund-Mercier, 1995; Huber et al., 2005;
Young et al., 2006; Raggenbass, 2008), and humans (Loup et al.,
1991)—influence the different roles of these two nonapeptides in
the CNS, and many models suggest these related peptides have
somewhat opposing roles in terms of anxiety and behavioral mea-
sures of coping (Legros, 2001; Neumann and Landgraf, 2012).
Notwithstanding this larger framework, evidence also exists sug-
gesting some of OTs activities, including both its putative central
therapeutic effects (Schorscher-Petcu et al., 2010; Sala et al.,
2011), as well as some of its potential side effects [i.e., hypona-
tremia (Seifer et al., 1985; Stratton et al., 1995)] may be mediated
by binding to AVP receptors (Liggins, 1963; Li et al., 2008).
A number of specific agonists and antagonists for each of
the four different nonapeptide receptors have been developed
(Manning et al., 2012), and have allowedmore precise delineation
of the role of the different receptors in the activities of each of
these nonapeptides. Specifically, whereas OT (but not AVP) nor-
malizes deficits in OT and CD38 knockout mice (Ferguson et al.,
2000; Jin et al., 2007), both OT and AVP normalize defects in
OT-receptor knockout mice, which demonstrate an autism-like
profile (deficits in social behavior, seizures) (Sala et al., 2013).
This latter experiment indicated that ICV delivery of both OT
and AVP reduced some of these autism-like difficulties via the
AVPV1a receptor (Sala et al., 2013). A second, related experi-
ment found that some of OTs analgesic activity in mice is related
to AVPV1a, as demonstrated by OT’s lack of analgesic activ-
ity in AVPR1a knockout mice and the ability of an AVPR1a
receptor antagonist to block the effect (Schorscher-Petcu et al.,
2010).
With regard to any putative therapeutic effect of OT, OT-
mediated activation of AVP receptors may have four potential
consequences on OT’s behavioral effects: potentiation, media-
tion, attenuation, or no impact. The same holds true for any
possible side effects of OT. Elucidating the role AVP receptor
activation plays in each of OT’s putative therapeutic effects is
therefore important in order to inform development of drugs to
optimally target central OT/AVP systems. Knowledge gained from
this effort would determine whether energy should be directed
toward developing OT agonists with greater selectivity for OTR
than OT itself, or toward compounds with more balanced affin-
ity for OTR and one or more AVP receptor types. Highlighting
this issue, a recent animal study revealed that AVP1a activa-
tion (via desmopressin, an AVP receptor agonist) and blockade
(via atosiban, an OT/AVP1a receptor antagonist) produced anx-
iogenic and anxiolytic effect, respectively (Mak et al., 2012).
Based on this, an OTR agonist with no cross-affinity for AVPR1a
would be expected to have superior anxiolytic efficacy and a
compound that acted as a dual OTR agonist/AVPR1a antagonist
might have even greater efficacy. Also worth mention here is a
very recent human trial of the vasopressin V1b receptor antago-
nist SSR149415, which showed negligible anxiolytic effects, and
antidepressant effects that warrant further study (Griebel et al.,
2012).
MONOTHERAPY vs. AUGMENTATION: CAN OXYTOCIN TREAT ON ITS
OWN OR IS IT BETTER SUITED TO AUGMENT OTHER ESTABLISHED
TREATMENTS?
The discovery of the molecular mechanisms wherein experience
becomes written in the nervous system (Kandel and Squire, 1999),
and the growing understanding that OT’s effects vary signifi-
cantly based on context (Bartz et al., 2011b), opens the possi-
bility for pharmacological augmentation of learning-based treat-
ments, including computer-based cognitive training programs
(i.e., Vinogradov et al., 2012) and many forms of psychother-
apy (see Choi et al., 2010). Several medications have already
been examined in this capacity, including the NMDA partial ago-
nist d-cycloserine (DCS) (Otto et al., 2010), the NMDA receptor
antagonist ketamine, (Krupitsky et al., 2002), the beta-blocker
propranolol (Kindt et al., 2009), and the serotonergic-enhancer
MDMA (“ecstasy”), an amphetamine-related CNS stimulant
which may exert some of its effects via the OT system (Parrott,
2007; Dumont et al., 2009). Evidence that OT enhances neuro-
genesis (Leuner et al., 2012), the beneficial effects of social sup-
port (Heinrichs et al., 2003), social salience and social memory
(Hurlemann et al., 2010; Guastella and MacLeod, 2012) also sug-
gest that OT is a good candidate for such “augmentation” trials.
In the case of schizophrenia, for example, it may be valuable
to examine OTs effects when given in conjunction with cogni-
tive enhancement therapies already demonstrated to have benefit
(Chou et al., 2012; Twamley et al., 2012). Aside from OT’s ability
to augment learning-based treatments, we note that OT’s bene-
fits in schizophrenia have all been when it is given in conjunction
with established antipsychotics (i.e., a pharmacological “augmen-
tation” strategy) (Feifel et al., 2010, 2012a; Pedersen et al., 2011;
Modabbernia et al., 2013) and that the role of OT as a primary
antipsychotic needs investigation.
More speculative, but related, is “OT therapy by proxy”
wherein OT given to an adult in a social context (i.e., parent and
child) may cause OT-driven changes in the child without direct
drug administration to this sensitive population (Naber et al.,
2010; Weisman et al., 2012b). Current studies of OT’s “augmen-
tation” effect in patients have been limited to one single-dose
study and have demonstrated limited success on primary clinical
endpoints (Guastella et al., 2009).
ARE THERE IDENTIFIABLE BIOMARKERS FOR OXYTOCIN’S
THERAPEUTIC EFFECTS?
Biomarkers are objectively measured characteristics that relate to
the cause, clinical course, and treatment of illness (Frank and
Hargreaves, 2003). In drug development, biomarkers optimize
the efficiency of clinical drug studies by facilitating the detection
of early signals of drug response (Wiedemann, 2011). Properties
of an optimal pharmacological biomarker include: high sensi-
tivity and specificity for clinical outcomes; relatively inexpen-
sive, and low-risk; interpretable by clinicians in many different
practice locations; a dose-response relationship; and a plausible
link with pharmacology and pathogenesis (Dumont et al., 2005;
Wiedemann, 2011; Baskaran et al., 2012; Leuchter et al., 2012).
For a variety of reasons—including a chasm between our under-
standing of the short-term neurobiological effects of drugs and
later clinical improvements—these characteristics are of special
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import in neuropsychiatry research (Wiedemann, 2011). In this
field, specifically, a wide variety of biomarkers relevant to OT are
in different stages of utilization and development, including lab-
oratory markers (serummarkers, genetic tests), electrophysiolog-
ical markers (EEG, MEG, facial EMG, GSR), brain imaging tech-
niques (fMRI, PET), and behavioral measures (challenge tests,
cue exposure tasks, PPI, fear-potentiated startle) (Wiedemann,
2011). Most of these putative biomarkers have been utilized in
conjunction with OT, and this is one arena where single-dose
OT studies have been invaluable in terms of OT’s development
as a pharmaceutical. Though there has been relatively little clin-
ically oriented biomarker research with OT (i.e., correlation of
a biomarker with meaningful clinical syndromes or outcomes),
the extant OT literature contains several promising candidates:
heart-rate variability (HRV) (Kemp et al., 2012), skin conduc-
tance (GSR) (de Oliveira et al., 2012b), stressed cortisol responses
(Ditzen et al., 2009; Quirin et al., 2011; Simeon et al., 2011;
Cardoso et al., 2012; Linnen et al., 2012), facial affect recog-
nition (Fu et al., 2007, 2008; Harmer et al., 2009a,b), pupil
responses (Leknes et al., 2012), EEG measures (Perry et al.,
2010), MEG (Hirosawa et al., 2012), and a variety of functional
imaging (fMRI) parameters, including alteration of default-mode
network (Sripada et al., 2013), responses to naturalistic social
stimuli (Riem et al., 2011, 2012), and stress-induced amygdala
responsivity and connectivity patterns (Labuschagne et al., 2010,
2011; Zink and Meyer-Lindenberg, 2012). Regarding functional
imaging biomarkers, these techniques would be greatly aided by
technical advances, especially a radionucleotide for OTRs. The
development of such a tracer—invaluable in the study of clinically
relevant aspects of central dopaminergic (Seeman and Tallerico,
1998; Volkow et al., 2001) and opiatergic systems (Greenwald
et al., 2003; Mitchell et al., 2012)—would aid in characterizing
the relationship between central OTR density, clinical pheno-
types, and treatment with OT. In vivo visualization of the human
OTR would be particularly fascinating given that (1) in animal
species, OTR distribution is a significant determinant of behav-
ior (Hammock and Young, 2006; Ross et al., 2009; Ophir et al.,
2012); and (2) OTR density appears to vary dynamically during
phases of life (Bale et al., 2001; Meddle et al., 2007). As well,
functional imaging studies demonstrating the cortical effects of
IN OT (Figure 1) and (Bethlehem et al., 2012) are vital addi-
tions to translational OT research, given the significant variability
of cortical organization among different species, including those
most frequently used in OT research (Preuss, 2000). Though a few
studies have examined post-mortem OTR binding in the human
CNS (using the same radiolabeled peptide as in rodents) (Loup
et al., 1989, 1991), synthesis of small-molecule radioligands for
the OTR (Smith et al., 2012), would greatly aid our understanding
of the functional role of the OT system in human brain disorders
and treatment.
To advance the therapeutic potential of OT, the abovemen-
tioned biomarkers need to be refined and applied to clinically
ill patients. These studies would clarify several basic pharmaco-
dynamics and pharmacokinetic questions surrounding OT (infra
supra), and—most importantly—could be used to predict ther-
apeutic response. Vitally, biomarker-guided clinical trials may
optimize the efficiency of future clinical trials, facilitating the
optimal use of a shrinking pool of funding for OT research
(driven in part by OT’s lack of patent exclusivity).
FROM DEARTH TO BIRTH, AND PRECLINICAL TO CLINICAL
RESEARCH—HELPING OXYTOCIN DELIVER
We believe the above review supports two broad conclusions
about OT as potential therapeutic agent for CNS disease. First,
the last decade of translational and clinical research has pro-
vided a great deal of reason to be cautiously optimistic that
OT-based treatments may be developed to help ease the dearth
in novel treatments for psychiatric illness. Secondly, and some-
what in contrast, the translation of OT’s therapeutic promise has
been remarkably slow, considering clinical studies with OT are
not hindered by the typical limitations imposed by non-approved
investigational drugs (i.e., costly animal and human safety and
toxicity testing before testing in proof-of-concept human trials).
As discussed above, single-dose studies in normal subjects—and
a much-smaller set of single-dose studies in clinical populations
(Table 1)—has left the field pregnant with anticipation about
OT’s potential therapeutic utility. In our opinion, however, direct
tests of this utility are now past due. We need to help OT
deliver.
The fact that there are only a few published small, multi-week
clinical trials of OT is problematic. More single-dose studies—
overwhelmingly in normal subjects—continue to be generated.
Some of these add to the body of support for therapeutic effects,
while others do the opposite, revealing a more complex role for
OT in human behavior, emotion, and cognition (De Dreu et al.,
2010, 2011). These complexity-revealing findings in particular
have spurred some investigators to suggest that it is premature
to speculate about OT’s therapeutic potential for neuropsychi-
atric disorders and opine that before we do clinical trials, the field
needs more translational studies to elucidate OT’s complex role
(e.g., Grillon et al., 2012; Miller, 2013).
As active clinicians and translational researchers, we recognize
the value of translational research. Faced daily with individuals
and families who have profound and often urgent need for bet-
ter treatments, however, we also recognize its limitations. While
we agree that additional preclinical OT research in animals and
humans is vital, we do not believe these trials should be done
at the expense of randomized controlled trials in clinical pop-
ulations. Instead, a stepwise, tandem progression is optimal.
Translational research works best in a bi-directional mode, with
preclinical studies informing clinical trials and the results of clini-
cal trials—in turn—helping identify which preclinical paradigms
have the best predictive validity for a specific disorder and drug
class. In this way, translational paradigms can be further leveraged
to conduct impactful preclinical research. Animal studies have the
ability to efficiently deliver clinically relevant information without
the expense, time, and risk-considerations inherent in human tri-
als. Similarly, preclinical human studies in which acute effects of
drugs, like OT, are examined on symptom proxies such as func-
tional imaging changes in clinically relevant circuits or laboratory
analogs of pathological conditions (e.g., CCK-induced panic) are
much easier, less expensive, and less risky than classic randomized
clinical trials. However, at present, the predictive validity of both
these forms of preclinical drug research with regard to psychiatric
www.frontiersin.org March 2013 | Volume 7 | Article 35 | 13
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disorders is far from perfect. Examples abound in which efficacy
or deleterious effects noted in clinical trials were not manifested
in preclinical studies and vice versa. Though clearly we sup-
port translational research and the ongoing search for reliable
biomarkers of clinical response in psychiatric illness, the sim-
ple facts are: rodents are not humans, and changes in functional
imaging or laboratory tasks are not the same as changes in clinical
symptoms.
As one can see in the abovementioned review, there is cur-
rently reasonably good evidence from animal and human pre-
clinical trials that OT may have therapeutic benefit in at least
three brain-based conditions: schizophrenia, anxiety, and autism.
For the myriad reasons discussed above, we believe that addi-
tional preclinical studies will not—by themselves—answer the
critical therapeutic questions that face clinicians in the field.
Therefore, proof-of-concept clinical trials are warranted. As a
point of comparison, phase II studies—the kind that are now
needed to directly test the various hypotheses regarding OT’s
therapeutic utility—have been carried out by industry on inves-
tigational agents with far less data supporting their efficacy and
safety. These facts, together with (1) the profound impairments
imposed by brain-based disease; (2) the often-inadequate efficacy
of extant treatment; and (3) a disheartening lack of promising,
novel treatments in the pipeline, we believe, justifies cautious
execution of clinical trials with OT in the abovementioned con-
ditions. In this regard it is noteworthy that—after a long period
of gestation—the water seems to have broken on research directly
testing OT’s clinical promise: several potentially seminal clinical
studies of OT appear be underway in several top “target” disorders
(www.clinicaltrials.gov).
However, OT will not be developed into a drug for any
psychiatric indication with one, two, or even three investigator-
initiated clinical trials. These initial trials often produce neg-
ative or weak therapeutic effects. Thus, concurrent preclinical
studies—both animal and human—are needed to advance the
therapeutic development of OT. These additional preclinical stud-
ies are needed to inform the design of the inevitable second
wave of clinical trials in the current “big three” indications, as
well as initial proof-of-concept trials in other emerging candi-
date OT-responsive disorders. For example, preclinical studies
demonstrating dichotomous dose-dependent effects on clinically
relevant measures may prompt research emphasis on wider dose
ranging in phase-II studies of OT. Likewise, animal studies show-
ing tolerance of clinically relevant preclinical effects after a certain
duration of treatment may prompt longer-duration trials to eval-
uate this effect in humans. Similarly, evidence of adverse effect
in animals emerging at certain doses or durations may prompt
incorporation of specific safety monitoring features into OT clin-
ical trials. This latter point is particularly important given that
randomized controlled trials are costly and labor-intensive, and
that negative results due to type-II errors (i.e., missing a signif-
icant therapeutic effect) for example, by infelicitous selection of
dose(s) or dosing frequency can be devastating to future studies.
To this end, there is a definitely a need for more translational
research using animal models with validity—particularly predic-
tive validity—for the specific conditions for which OT is a can-
didate treatment (e.g., autism, schizophrenia, anxiety, etc.). Such
studies will help address the vital questions we have delineated
in this paper. These animal studies should be complemented by
translational human studies using single doses and non-symptom
outcomes. Knowledge derived from both of these approaches will
increase the likelihood of success of critical clinical trials. As men-
tioned above, the third element in the bench-to-beside arc are
clinical trials using OT, which can reciprocally provide useful
information to evaluate the predictive validity of various animal
models and proxy-symptom human paradigms.
In light of these facts, and in light of the prodigious amount
of animal and human OT research, it is surprising how little
effort has been specifically directed to address the translational
questions delineated above. For example, despite good evidence
from preliminary clinical trials that OT has therapeutic benefit in
schizophrenia (MacDonald and Feifel, 2012a), at the time of this
writing, only three published studies have explored exogenous
OT’s effects in animals models with predictive relevance specif-
ically for schizophrenia (Feifel and Reza, 1999; Lee et al., 2005;
Feifel et al., 2012b). In order to help OT deliver on its therapeutic
promise, there remains much work across the entire translational
spectrum.
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